Nuclide new terminal here
Food and Drug Administration) marked a breakthrough in targeted radionuclide imaging and therapy and has provided impetus for further development in nuclear oncology.
Recent approval of the peptide-based agents Ga-DOTATATE, Lu-DOTATATE and Ga-DOTATOC by the FDA (U.S. A cross-fire effect is also helpful in overcoming an intratumoral heterogeneity of a target expression. Radionuclide therapy is not subject to multidrug resistance, which is often the case for chemotherapy. For therapeutic purposes, emitters of alpha and beta particles, as well as Auger electrons, can be utilized. By providing additional information, radionuclide molecular imaging helps clinicians in the diagnosis and staging of cancer, as well as in the development of treatment strategies and in the monitoring of target expression in response to treatment. As a noninvasive procedure that can be performed repeatedly, it can overcome some of the limitations of conventional biopsy-based diagnostics, which include: a limited number of samples, the inability to sample certain locations, the heterogeneity of target expression as well as the changes in expression over time. Radionuclide molecular imaging allows for the whole-body evaluation of cancer-associated targets expressed in real time and therefore aims to make cancer treatment personalized and more effective. Positron-emitting radionuclides are used for positron emission tomography (PET) imaging, while gamma-emitters are best suited for single-photon emission computed tomography (SPECT) imaging. Radiopharmaceuticals are designed to precisely deliver a radionuclide to cancer-associated molecular targets with either diagnostic or therapeutic purposes. The interest in using targeted radiopharmaceuticals in nuclear oncology has increased in recent years and continues to grow.